Pharma BD Deal Intelligence
GSK licensed rights to Adaptimmune's NY-ESO-1 SPEAR T-cell program in a $500M option-milestone collaboration but never launched a product from it. GSK exercised the option in 2017, advanced the therapy through clinical trials, then exited cell and gene therapy in 2023 and handed the program back to Adaptimmune.
Not actually an acquisition — a GSK cell-therapy licensing bet that GSK later reversed entirely, handing the asset back to Adaptimmune after exiting the modality
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Expanded agreement could yield ~$500M in NY-ESO development milestones; GSK effectively funds the pivotal synovial sarcoma studies and shares combination-study…
GSK and Adaptimmune expand their cancer immunotherapy collaboration, with up to eight proof-of-principle combination studies including checkpoint inhibitors…
GSK confirmed full transition of the NY-ESO SPEAR T-cell programme from Adaptimmune, taking sole responsibility for development and commercialization following…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Adaptimmune and GSK expanded their June 2014 strategic collaboration to accelerate development of NY-ESO SPEAR T-cell therapy toward registration trials in synovial sarcoma and exploration in MRCLS. Under the expanded terms, Adaptimmune was eligible for up to ~$500M in incremental development milestones for NY-ESO program alone if GSK exercised its option and successfully developed in multiple indications/HLA types. GSK retained option rights pending Phase 1 data review.
Not actually an acquisition — a GSK cell-therapy licensing bet that GSK later reversed entirely, handing the asset back to Adaptimmune after exiting the modality
Assessment window: 10yr post-close.
800 US cases/yr
Synovial sarcoma is a rare, aggressive soft-tissue sarcoma driven by a pathognomonic SS18-SSX gene fusion, most often arising in the extremities of adolescents and young adults aged 15-40. About 800-1,000 new cases are diagnosed annually in the US; metastatic/unresectable disease has historically had limited durable options after doxorubicin- and ifosfamide-based chemotherapy fails.
Standard care for advanced synovial sarcoma at deal time was anthracycline/ifosfamide chemotherapy, with later-line use of pazopanib (Votrient, Novartis/GSK) for soft-tissue sarcoma and trabectedin (Yondelis, Janssen/PharmaMar) for liposarcoma/leiomyosarcoma — none with durable disease control in synovial sarcoma. NY-ESO-1 is expressed in roughly 70-80% of synovial sarcomas, making it an attractive cell-therapy target, and Adaptimmune's affinity-enhanced TCR (later afami-cel/Tecelra) showed a 50% response rate (6/12) in early synovial-sarcoma cohorts. The expanded February 2016 GSK collaboration accelerated NY-ESO toward registration trials in synovial sarcoma and exploration in MRCLS, with up to eight proof-of-principle combination studies (including checkpoint inhibitors) and added incremental milestones on top of the June 2014 master agreement. The deal validated TCR cell therapy in solid tumors years before the August 2024 Tecelra approval (the first engineered cell therapy in a solid tumor) and shaped the pivotal SPEARHEAD-1 trial that ultimately supported registration after GSK returned the program to Adaptimmune in 2021.
Myxoid/round cell liposarcoma (MRCLS) is a rare adipocytic soft-tissue sarcoma defined by FUS-DDIT3 (or rarely EWSR1-DDIT3) translocations, accounting for roughly a third of liposarcomas. Like synovial sarcoma it expresses NY-ESO-1 at high frequency, making it an explore-worthy second indication for SPEAR T-cell therapy.
MRCLS treatment at deal time relied on doxorubicin-based chemotherapy in advanced disease, with trabectedin (Yondelis) holding a particular niche given its activity in translocation-driven liposarcomas, and eribulin (Halaven) approved in 2016 specifically for liposarcoma. The expanded GSK-Adaptimmune agreement specifically called out exploration of NY-ESO SPEAR T cells in MRCLS alongside the synovial-sarcoma registration push, positioning TCR therapy as a potential first-in-class option in a translocation-driven solid tumor with limited durable systemic options. While the synovial-sarcoma program ultimately reached approval, the MRCLS arm remained earlier-stage and was part of the broader portfolio Adaptimmune reclaimed when GSK returned the program in 2021.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Adaptimmune Therapeutics plc / GlaxoSmithKline plc (this deal) | 2016 | $500M | 16 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc. | 2020 | $2.0B | 91 |
← Browse all deals · How we score deals
More: 2016 deals · Oncology deals